Breyanzi is named as an intervention in 6 current clinical trials in our USA, Germany, France, Canada, Israel, UK, Spain, Italy, Sweden, Austria, Japan and Mexico registers. 3 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Celgene (1). The most-studied condition is Lymphoma, Non-Hodgkin.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Lymphoma, Non-Hodgkin | 1 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 |
| Lymphoma, Small Lymphocytic | 1 |
| Lymphoma | 1 |
| Large B-cell Lymphoma | 1 |
| Lymphoma, B-Cell | 1 |
| Relapsed Non-Hodgkin Lymphoma | 1 |
| Refractory Non-Hodgkin Lymphoma | 1 |
| Diffuse Large B-Cell Lymphoma | 1 |
| Grade 3b Follicular Lymphoma | 1 |
| Primary Mediastinal (Thymic) Large B-Cell Lymphoma | 1 |
| Recurrent Diffuse Large B-Cell Lymphoma | 1 |
| Refractory Aggressive B-cell Lymphomas | 1 |
| Refractory B-Cell Non-Hodgkin Lymphoma | 1 |
| Aggressive B-cell NHL | 1 |
| Diffuse Large B-cell Lymphoma (DLBCL) | 1 |
| Lead sponsor | Trials |
|---|---|
| Celgene | 1 |
| Juno Therapeutics, a Subsidiary of Celgene | 1 |
| Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 1 |
| Lyell Immunopharma, Inc | 1 |
| SWOG Cancer Research Network | 1 |
| Patrick C. Johnson, MD | 1 |
A trial with sites in more than one country appears in each of those registers.
6 current trials in our USA, Germany, France, Canada, Israel, UK, Spain, Italy, Sweden, Austria, Japan and Mexico registers name Breyanzi (also registered as JCAR017) as a drug or biological intervention, as of the registry sync on 29 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 6 trials are recruiting: 2 with sites in USA, 1 with sites in Germany, 1 with sites in France and 1 with sites in Mexico. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Celgene (1), Juno Therapeutics, a Subsidiary of Celgene (1), Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (1) and Lyell Immunopharma, Inc (1), among 6 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Breyanzi works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Breyanzi works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Breyanzi (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 29 Sep 2026.